# Pathogenetix

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pathogenetix

- Industry: Biotechnology
- Headquarters: Woburn, US
- Website: www.pathogenetix.com
- Total disclosed funding: $47M
- Latest round: Series C (Oct 30, 2013)
- Investors on record: 7

## About

Pathogenetix is a biotechnology company specializing in rapid pathogen identification through advanced genomic analysis solutions, enhancing decision-making in critical sectors such as healthcare and food safety.Founded in 1997 and headquartered in Woburn, US, Pathogenetix focuses on genomic analysis for pathogen identification. The company was a target in a Series C funding round that raised USD 10.00 mn, with its most recent deal occurring on February 13, 2015. Hamid Shirkhan serves as the CEO.Pathogenetix specializes in advanced genomic analysis solutions, primarily focusing on rapid and accurate pathogen identification. Their core product offerings include a sophisticated platform that utilizes proprietary technology for sequencing and analyzing microbial DNA, instrumental in applications like food safety, clinical diagnostics, and environmental monitoring. The company provides real-time insights into pathogen presence, enhancing decision-making for healthcare providers, food manufacturers, and environmental agencies worldwide, particularly in North America, Europe, and Asia.Pathogenetix generates revenue through B2B partnerships and direct sales to institutional clients, including hospitals, laboratories, and food safety authorities. Revenue streams primarily stem from the sale of its genomic analysis platform and associated services such as support and maintenance, typically following a subscription model or one-time licensing agreements. These transactions are tailored to meet clients' operational needs and regulatory requirements.Pathogenetix plans to expand its portfolio with new product launches expected to enhance pathogen detection capabilities. The company is targeting expansion into the European and Asian markets by the end of 2016. The recent funding of USD 10.00 mn will support these initiatives, particularly in technological advancements and market penetration strategies. In February 2015, Pathogenetix’s Pathogen ID Technology was acquired by Toxic Reports, indicating a strategic shift and potential new directions for the company.

## Funding rounds

- Series C, Oct 30, 2013, $10M — HealthCare Ventures, Ascension Ventures, Excel Venture Management
- Series B, Nov 1, 2011, $7.5M — HealthCare Ventures, CB Health Ventures, Ascension Ventures, Excel Venture Management
- Series B, Aug 1, 2011, $4M — HealthCare Ventures, CB Health Ventures, Excel Venture Management
- Series D, May 5, 2003, $25M — HealthCare Ventures, Zero Stage Capital, CB Health Ventures, CDIB Capital Group, F-Prime Capital

## Investors

- HealthCare Ventures — Series D, Series B, Series C
- Zero Stage Capital (https://capitalatlas.ai/funds/zero-stage-capital) — Series D
- CB Health Ventures (https://capitalatlas.ai/funds/cb-health-ventures) — Series D, Series B
- CDIB Capital Group (https://capitalatlas.ai/funds/cdib-capital-group) — Series D
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series D
- Excel Venture Management (https://capitalatlas.ai/funds/excel-venture-management) — Series B, Series C
- Ascension Ventures (https://capitalatlas.ai/funds/ascension-ventures) — Series B, Series C